AIStockmoo 评分
| 价值 30% | -3.8 |
| 资本回报低于资本成本。资本回报下降。 参考 | |
| 负债低。盈利能力弱。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | -4.4 |
| 过去一年呈下降趋势。股价远低于52周高点。 参考 | |
| 下降趋势,但均线已走平。股价接近均线。放量跌破均线。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 持仓情绪 参考 | NA |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | -0.5 |
| 机构在最新13F申报中净-0.25%的股份:22家增持,8家减持(截至30 Sep 2026的季度)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 每股盈利逐年上升。近年曾亏损。 参考 | |
| 低于中期趋势线。 参考 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短、中、长期趋势均向下。短期动能下降。 参考 | |
| 股价接近支撑位。 参考 | |
| 最终评分 | -3.67 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Cel-Sci Corporation | - | - |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| CVM | 21 M | - | - | 2.22 | -3.7 |
| CYBN | 359 M | - | - | - | 0.0 |
| NRXS | 60 M | - | - | 18.58 | -1.2 |
| NHWK | 20 M | - | - | 0.260 | 0.0 |
| AEON | 10 M | - | - | - | -3.3 |
| TOVX | 6 M | - | 0.099 | 0.610 | -2.7 |
|
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 3.71% |
| 机构持股比例 | 14.60% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Mai Capital Management | 30 Sep 2026 | 109,280 |
该时间范围内无数据。
机构
机构持股比例: 12.94%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 22 | 196,419 |
| 减持 | 8 | 208,017 |
| 新建仓 | 7 | 29,620 |
| 清仓 | 3 | 62,567 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
| 日期 | 类型 | 细节 |
|---|---|---|
| 20 Nov 2026 | Yahoo Finance |
CEL-SCI’s Multikine® Receives Saudi FDA NADR Designation, Accelerating Potential Commercial Launch
VIENNA, Va., November 20, 2026--CEL-SCI’s Multikine receives Saudi FDA NADR Designation, accelerating potential commercial launch. |
| 10 Nov 2026 | Yahoo Finance |
CEL-SCI’s Dr. Eyal Talor Receives Second International Keynote Invitation on Multikine Head and Neck Cancer Research
VIENNA, Va., November 10, 2026--CEL-SCI’s Dr. Eyal Talor receives second international keynote invitation on Multikine head and neck cancer research. |
| 29 Oct 2026 | Yahoo Finance |
CEL-SCI reports 73.4% five-year survival in Multikine Phase 3 patient analysis
CEL-SCI Corporation CEO Geert Kersten joined Steve Darling from Proactive to discuss new tumor-response and safety analyses from the company’s completed Phase 3 study of Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy for head and neck cancer. The findings were… |
| 26 Oct 2026 | Yahoo Finance |
CEL-SCI Presents New Phase 3 Multikine® Data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival
VIENNA, Va,, October 26, 2026--CEL-SCI presents Phase 3 Multikine data at World Congress: Pre-Surgical Biomarkers Identify Head & Neck Cancer Patients Achieving 73% 5-Year Survival. |
| 15 Sep 2026 | Yahoo Finance |
CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology
VIENNA, Va., September 15, 2026--CEL-SCI invited to deliver keynote address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology. |
技术形态 中期
AI 技术分析
投资组合